{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280620","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.642765+00:00","generated_at":"2026-06-22T01:28:53.704495+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"UroGen Pharma appoints Daniel G. Wildman to board of directors","bullets":["Daniel G. Wildman appointed to fill a board vacancy effective November 8, 2022.","Initial option grant of 20,000 ordinary shares, vesting in equal quarterly installments over 12 quarters.","Annual retainer of $40,000 for board service plus $5,000 for service on the Compliance Committee.","Eligible for annual option grant of 10,000 ordinary shares at each annual shareholder meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280620","json":"https://secwatch.observer/filing/0001193125-22-280620.json","markdown":"https://secwatch.observer/filing/0001193125-22-280620.md","text":"https://secwatch.observer/filing/0001193125-22-280620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/0001193125-22-280620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/d353119d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:28:53.704495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb12c4151f","claim":"Daniel G. Wildman was appointed as Director at UroGen Pharma Ltd..","evidence_excerpt":"On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522280620/0001193125-22-280620-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}